Dated: March 5, 2013.

Leslie Kux,

Assistant Commissioner for Policy.

[FR Doc. 2013–05471 Filed 3–7–13; 8:45 am]

BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Report on Carcinogens Webinar on Pentachlorophenol; Notice of Public Webinar and Registration Information

SUMMARY: The National Toxicology Program (NTP) announces a public webinar, ''Human cancer studies on exposure to pentachlorophenol (PCP): Differentiating potential cancer effects of PCP exposure from effects due to occupational co-exposures or PCP contaminants.'' The Office of the Report on Carcinogens (ORoC), Division of the NTP (DNTP), National Institute of Environmental Health Sciences (NIEHS) will hold the webinar using Adobe® Connect™, and the public can register to attend.

DATES:

Webinar: April 11, 2013, 12:30 p.m. to approximately 5:00 p.m. Eastern Daylight Time (EDT).

Pre-Registration for Webinar: March 8, 2013 to April 8, 2013.

ADDRESSES:

Webinar Web page: The agenda, speaker abstracts, registration, and other meeting materials are at *http://ntp.niehs.nih.gov/go/pcpwebinar.*

FOR FURTHER INFORMATION CONTACT: Dr. Ruth M. Lunn, Director, ORoC, DNTP, NIEHS, P.O. Box 12233, MD K2–14, Research Triangle Park, NC 27709. Phone: (919) 316–4637; Fax: (301) 480–2970, Email: *lunn@niehs.nih.gov.* Hand Delivery/Courier: 530 Davis Drive, Room 2138, Morrisville, NC 27560.

SUPPLEMENTARY INFORMATION:

Background: The Report on Carcinogens (RoC) is a congressionally mandated, science-based, public health report that identifies agents, substances, mixtures, or exposures (collectively called ''substances'') in our environment that are cancer hazards for people living in the United States. The NTP prepares the RoC on behalf of the Secretary of Health and Human Services following an established, four-part process (*http://ntp.niehs.nih.gov/go/rocprocess*).

PCP, including its sodium salt, is a chlorinated aromatic compound that is used primarily as a wood preservative in the United States. It was selected as a candidate substance following solicitation of public comment and review by the NTP Board of Scientific Counselors on June 21–22, 2012 (*http://ntp.niehs.nih.gov/go/9741*) (for more information on the status of NTP review of PCP see *http://ntp.niehs.nih.gov/go/37897*).

The objective of the webinar is to provide scientific input to the ORoC on issues related to its approach for evaluating the epidemiologic studies on exposure to PCP and not to receive recommendations from invited speakers or the public on whether or not PCP should be listed in the RoC. The webinar will consist of (1) four presentations, each of which will be followed by a short question and answer period specific for the presentation, and (2) a discussion session across presentations. The goals of the individual presentations are (1) to identify occupational co-exposures and PCP components or contaminants in human epidemiologic studies of exposure to PCP, (2) to identify which co-exposures should be considered as potential confounders, and (3) to discuss the methods used in the epidemiologic studies to evaluate confounding.

Webinar and Registration: The webinar is scheduled for April 11, 2013, from 12:30 to approximately 5 p.m. e.d.t. The webinar may end early if the presentations and general discussion period are finished. The public may register for the webinar beginning March 8, 2013, through April 8, 2013, at *http://ntp.niehs.nih.gov/go/pcpwebinar.* There will be 50 connections available on a first-come, first-served basis for registrants. Registrants will receive instructions by email to access the webinar (via Adobe® Connect™) on or before April 9, 2013.

The preliminary agenda, list of speakers, and abstracts of the presentations should be posted on the NTP Web site (*http://ntp.niehs.nih.gov/go/pcpwebinar*) by March 26, 2013. Registrants are encouraged to access the webinar Web page to stay abreast of the most current information regarding this event. Any updates will be posted to the Web site.

Public Participation: Time will be set aside following each presentation and during the general discussion period after the talks are finished for the public to ask questions or make brief remarks. Instructions for participating in the meeting via Adobe® Connect™ will be included in the information for accessing the webinar. Individuals with disabilities who need accommodation to participate in this event should contact Dr. Lunn. TTY users should contact the Federal TTY Relay Service at 800–877–8339. Requests should be made at least five business days in advance of the event.

Background Information on the RoC: Published biennially, each edition of the RoC is cumulative and consists of substances newly reviewed in addition to those listed in previous editions. The 12th RoC, the latest edition, was published on June 10, 2011 (available at *http://ntp.niehs.nih.gov/go/roc12*). The 13th RoC is under development. For each listed substance, the RoC contains a substance profile, which provides information on: Cancer studies that support the listing—including those in humans, animals, and studies on possible mechanisms of action—information about potential sources of exposure to humans, and current Federal regulations to limit exposures.

Dated: March 4, 2013.

John R. Bucher,

Associate Director, National Toxicology Program.

[FR Doc. 2013–05405 Filed 3–7–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of General Medical Sciences; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel; Review K99 Grant Applications.

Date: April 3, 2013.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: John J. Laffan, Ph.D., Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, 45 Center Drive, Room 3An.18J, Bethesda, MD 20892, 301–594–2773, *laffanjo@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives, National Institutes of Health, HHS)

Dated: March 4, 2013.

Melanie J. Gray,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013–05369 Filed 3–7–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Eye Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Eye Institute Special Emphasis Panel; NEI Pathways to Independence (K99) Applications.

Date: March 27–28, 2013.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 5635 Fishers Lane, Bethesda, MD 20892, (Virtual Meeting).

Contact Person: Brian Hoshaw, Ph.D., Scientific Review Officer, Division of Extramural Research, National Eye Institute, National Institutes of Health, 5635 Fishers Lane, Suite 1300, MSC 9300, 301–451–2020, *hoshawb@mail.nih.gov*.

Name of Committee: National Eye Institute Special Emphasis Panel; NEI Loan Repayment Program.

Date: April 9–11, 2013.

Time: 9:00 a.m. to 11:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 5635 Fishers Lane, Bethesda, MD 20892, (Virtual Meeting).

Contact Person: Anne E Schaffner, Ph.D., Chief, Scientific Review Branch, Division of Extramural Research, National Eye Institute, National Institutes of Health, 5635 Fishers Lane, Suite 1300, MSC 9300, 301–451–2020, *aes@nei.nih.gov*.

(Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, HHS).

Dated: March 4, 2013.

Melanie J. Gray,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013–05368 Filed 3–7–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2); notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel; NCI Experimental Therapeutics Program (NExT).

Date: April 24, 2013.

Time: 8:30 a.m. to 4:30 p.m.

Agenda: To evaluate the NCI Experimental Therapeutics Program Portfolio.

Place: National Institutes of Health, 9000 Rockville Pike, Building 45, Conference Room D, Bethesda, MD 20892.

Contact Persons: Barbara Mroczkowski, Ph.D., Executive Secretary, Discovery Experimental Therapeutics Program, National Cancer Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, MD 20892, (301) 496–4291, *mroczkoskib@mail.nih.gov*.

Joseph Tomaszewski, Ph.D., Executive Secretary, Development Experimental Therapeutics Program, National Cancer Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, MD 20892, (301) 496–6711, *tomaszej@mail.nih.gov*.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: March 4, 2013.

Melanie J. Gray,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013–05367 Filed 3–7–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting hosted by the Scientific Management Review Board.

The NIH Reform Act of 2006 (Pub. L. 109–482) provides organizational authorities to HHS and NIH officials to: (1) Establish or abolish national research institutes; (2) reorganize the offices within the Office of the Director, NIH including adding, removing, or transferring the functions of such offices or establishing or terminating such offices; and (3) reorganize divisions, centers, or other administrative units within an NIH national research institute or national center including adding, removing, or transferring the functions of such units, or establishing or terminating such units. The purpose of the Scientific Management Review Board (also referred to as SMRB or Board) is to advise appropriate HHS and NIH officials on the use of these organizational authorities and identify the reasons underlying the recommendations.

The meeting will be open to the public through teleconference at the number listed below.

Name of Committee: Scientific Management Review Board.

Date: March 19, 2013.

Time: 11:00 a.m. to 1:00 p.m.

Agenda: The meeting will focus on the findings and recommendations of the SBIR/STTR Working Group. The full Board will review and vote on the draft report from the Working Group. Time will be allotted on the agenda for public comment. Further